[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,146
  • Shares Outstanding, K 9,010
  • Annual Sales, $ 120,770 K
  • Annual Income, $ 32,690 K
  • EBIT $ -6 M
  • EBITDA $ -4 M
  • 60-Month Beta -0.30
  • Price/Sales 0.70
  • Price/Cash Flow 1.93
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.19
  • Growth Rate Est. (year over year) +525,689.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.52 +105.53%
on 04/29/26
12.45 -25.38%
on 05/07/26
+4.30 (+86.17%)
since 04/21/26
3-Month
3.92 +136.99%
on 02/23/26
12.45 -25.38%
on 05/07/26
+5.11 (+122.25%)
since 02/20/26
52-Week
3.92 +136.99%
on 02/23/26
19.15 -51.48%
on 01/05/26
+2.39 (+34.64%)
since 05/21/25

Most Recent Stories

More News
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and certain...

ATRA : 9.34 (-1.16%)
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options

ATRA : 9.34 (-1.16%)
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 22, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on...

ATRA : 9.34 (-1.16%)
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA

NEW YORK , May 20, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc." or the "Company") (NASDAQ: ATRA) of a class action...

ATRA : 9.34 (-1.16%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , May 19, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA...

ATRA : 9.34 (-1.16%)
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm

NEW YORK , May 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) .

ATRA : 9.34 (-1.16%)
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , May 18, 2026 /PRNewswire/ --

ATRA : 9.34 (-1.16%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , May 15, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

ATRA : 9.34 (-1.16%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and certain...

ATRA : 9.34 (-1.16%)
ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options

ATRA : 9.34 (-1.16%)

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 10.35
2nd Resistance Point 9.99
1st Resistance Point 9.72
Last Price 9.34
1st Support Level 9.09
2nd Support Level 8.73
3rd Support Level 8.46

See More

52-Week High 19.15
Fibonacci 61.8% 13.33
Fibonacci 50% 11.53
Fibonacci 38.2% 9.74
Last Price 9.34
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.